Calando Pharmaceuticals, UCLA Medical Center, City of Hope plan to conduct first cancer clinincal trial for RNAi therapeutics
First Human Trials Using Targeted, Formulated siRNA to use NA interference Against Cancer
15-May-2007 -
Calando Pharmaceuticals, together with City of Hope (COH) and the UCLA Jonsson Cancer Center (UCLA), announced that Calando, UCLA and COH are planning a broad-based Phase I clinical trial to begin later this year for Calando's lead drug candidate, CALAA-01, a nanoparticle containing ...
clinical trials
food
regulatory approval
+2